Biocartis

02/02/2026

💡𝗟𝗼𝗼𝗸𝗶𝗻𝗴 𝗳𝗼𝗿 𝗮 𝗳𝗮𝘀𝘁, 𝗰𝗼𝘀𝘁-𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝘄𝗮𝘆 𝘁𝗼 𝗱𝗲𝘁𝗲𝗰𝘁 𝗣𝗜𝗞𝟯𝗖𝗔 & 𝗔𝗞𝗧𝟭 𝗺𝘂𝘁𝗮𝘁𝗶𝗼𝗻𝘀?

Discover the 𝗨𝗣𝗗𝗔𝗧𝗘𝗗 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗜𝗞𝟯𝗖𝗔-𝗔𝗞𝗧𝟭 𝗠𝘂𝘁𝗮𝘁𝗶𝗼𝗻 𝗔𝘀𝘀𝗮𝘆:
✅ 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗰𝗼𝘃𝗲𝗿𝗮𝗴𝗲: Detection of 13 PIK3CA mutations and 1 AKT1 mutation
✅ 𝗠𝗶𝗻𝗶𝗺𝗮𝗹 𝘀𝗮𝗺𝗽𝗹𝗲 𝗿𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁𝘀: Directly from 1 FFPE tissue section (5 - 10 µm) with hands-on time under 3 minutes
✅ 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄: Single-use cartridge, cost-effective, no batching required
✅ 𝗣𝗿𝗼𝘃𝗲𝗻 𝗮𝗰𝗰𝘂𝗿𝗮𝗰𝘆: 97% overall concordance versus NGS and real-time PCR tests*

👉 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://www.biocartis.com/en/research/research-assays/idylla-pik3ca-akt1-mutation-assay-0?utm_source=facebook&utm_medium=social&utm_campaign=0202_mutation-assay


For Research Use Only (RUO), not for use in diagnostic procedures.

30/01/2026

💡𝗢𝗣𝗗𝗜𝗩𝗢® (𝗻𝗶𝘃𝗼𝗹𝘂𝗺𝗮𝗯) 𝗽𝗹𝘂𝘀 𝗬𝗘𝗥𝗩𝗢𝗬® (𝗶𝗽𝗶𝗹𝗶𝗺𝘂𝗺𝗮𝗯) 𝘄𝗮𝘀 𝗙𝗗𝗔-𝗮𝗽𝗽𝗿𝗼𝘃𝗲𝗱 as a new 1L ICI option for MSI-H/dMMR mCRC patients based on outcomes from the CheckMate-8HW trial(1,2)

In CheckMate-8HW, the 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗖𝗗𝘅 𝗠𝗦𝗜 𝗧𝗲𝘀𝘁 was used to establish the primary endpoints, revealing 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀 compared with local testing, as reflected in both the hazard ratio (0.20 vs 0.32) and ORR (74% vs 64%) (2)

🔍This analysis indicates that the 14% discordance rate between Idylla™ and locally obtained dMMR/MSI-H results was due to false positives from the local testing method - 𝗺𝗶𝘀𝗰𝗹𝗮𝘀𝘀𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗵𝗮𝘁 𝗹𝗶𝗸𝗲𝗹𝘆 𝗱𝗶𝗹𝘂𝘁𝗲𝗱 𝘁𝗵𝗲 𝗼𝗯𝘀𝗲𝗿𝘃𝗲𝗱 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗲𝗳𝗳𝗶𝗰𝗮𝗰𝘆.

👉 The Idylla™ CDx MSI Test is an accurate diagnostic solution that supports precision medicine at its best: ensuring the right patient receives the right treatment for the best possible outcomes. 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://www.biocartis.com/en-US/meet-idylla/idylla-oncology-assays/idylla-cdx-msi-test


Approved in the US under P250005. OPDIVO® and YERVOY® are registered trademarks of Bristol-Myers Squibb Company.
(1) https://doi.org/10.1056/NEJMoa2402141; https://doi.org/10.1016/S0140-6736(24)02848-4;
(2) https://doi.org/10.1200/JCO.2025.43.16_suppl.3501

29/01/2026

Revolutionize your CRC diagnostics with Idylla™ 🏆
⏱️Speed up your therapy decisions and alleviate patient anxiety*!

Test for MSI, KRAS, NRAS and BRAF in only 3 hours and immediately start the right therapy.

Rapidly identify patients eligible for immunotherapy through MSI, and targeted therapy with RAS and BRAF, ensuring they receive the most effective treatment without delay.

👉 Read morehttps://www.biocartis.com/sites/default/files/2024-09/colorectal-leaflet-august2024.pdf

Your patients, our priority. Guiding them to the right therapy within hours ⚡


*Miles, A. (2018). The Psychological Implications of Diagnostic Delay in Colorectal Cancer Patients. In: Olsson, L. (eds) Timely Diagnosis of Colorectal Cancer. Springer, Cham.

26/01/2026

As we enter 2026, we’re excited to reflect on the achievements that shaped our journey in 2025 💭
🎉 Join us every Monday this January for as we look back at our 2025 milestones!

Today we are reflecting on the ⭐𝟒𝟎+ 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬⭐ published in 2025!
These studies underscore Idylla™'s role in enhancing diagnostic speed, accuracy, and accessibility, ultimately improving patient care worldwide.
👏 Huge thanks to all who collaborated on these publications, we are grateful for your continued support!

🔎 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐚𝐥𝐥 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐨𝐧 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://www.biocartis.com/en/meet-idylla/publications?utm_source=facebook&utm_medium=social&utm_campaign=2601_publications

23/01/2026

𝗛𝗮𝘃𝗶𝗻𝗴 𝗮 𝗴𝗿𝗲𝗮𝘁 𝗳𝗶𝗿𝘀𝘁 𝗱𝗮𝘆 𝗮𝘁 𝗕𝗮𝗺𝗯𝗲𝗿𝗴𝗲𝗿 𝗠𝗼𝗿𝗽𝗵𝗼𝗹𝗼𝗴𝗶𝗲𝘁𝗮𝗴𝗲!
📅 23-25 January | 🗺️ Bamberg, Germany

📣𝗗𝗼𝗻'𝘁 𝗺𝗶𝘀𝘀 𝗼𝘂𝘁 𝗼𝗻 𝗼𝘂𝗿 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗘𝗚𝗙𝗥 𝗰𝗼𝗺𝗽𝗮𝗰𝘁 𝗰𝗼𝘂𝗿𝘀𝗲! Join us 24 January at 09:30 in room K8 and learn how Idylla™ can deliver your EGFR results in only 3 hours!

👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗕𝗮𝗺𝗯𝗲𝗿𝗴 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://lnkd.in/ebxNDcKu

23/01/2026

𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐏𝐎𝐋𝐄-𝐏𝐎𝐋𝐃𝟏 𝐌𝐮𝐭𝐚𝐭𝐢𝐨𝐧 𝐀𝐬𝐬𝐚𝐲*
✅ Molecular classification of samples in ~ 95 min.
✅ Covers 99% of the known pathogenic & mutations
✅ Achieved 98.2% accuracy with 450+ endometrial cancer samples (Barault et al., 2024)
✅ Fit for use on small biopsies & directly from 1 FFPE tissue section
✅ No need for sample batching
✅ Straightforward results reporting

👉 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 https://www.biocartis.com/en/research/research-assays/idylla-pole-pold1-mutation-assay?utm_source=facebook&utm_medium=social&utm_campaign=2301_idylla-pole-pold1-mutation-assay

*For Research Use Only (RUO), not for use in diagnostic procedures.
Barault, L. et al. (2024). The Idylla™ POLE Mutation Assay, A New Tool For Direct Mutation Detection From FFPE Tissue. AMP 2024 Annual Meeting

23/01/2026

23/01/2026

Join us at the 𝗕𝗲𝗹𝗴𝗶𝗮𝗻 𝗪𝗲𝗲𝗸 𝗼𝗳 𝗣𝗮𝘁𝗵𝗼𝗹𝗼𝗴𝘆 𝟮𝟬𝟮𝟲 in Brussels, Belgium 👋

Curious about getting your molecular biomarker results in 𝗼𝗻𝗹𝘆 𝟯 𝗵𝗼𝘂𝗿𝘀 with Idylla™? ⏱️
Join Mieke and Marc at our booth - they’re ready to walk you through the specifics!

👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://www.biocartis.com/en/news-events/events/belgian-week-of-pathology-2026
👉 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://www.biocartis.com/en/meet-idylla

21/01/2026

💡 Early detection and prompt treatment are crucial for lung cancer patients
Test for EGFR, ALK, ROS1, RET and METex14 in ONLY 3 HOURS and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers*.

IDYLLA™ FIRST. Guiding First-Line Therapy Decisions in NSCLC ⏱️

Learn more 👉🏻https://www.biocartis.com/sites/default/files/2025-06/idylla_first-line_lung_1l_-_leaflet_-_may2025.pdf


*Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

19/01/2026

As we enter 2026, we’re excited to reflect on the achievements that shaped our journey in 2025 💭
🎉 Join us every Monday this January for as we look back at our 2025 milestones!

Today we are reflecting on some of our ⭐𝟐𝟎𝟐𝟓 𝐜𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐡𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬⭐
and many more...

👋 We are looking forward to meeting you again in 2026!
Can't wait for next conference? 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐲𝐨𝐮𝐫 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐝𝐞𝐦𝐨 𝐧𝐨𝐰: https://www.biocartis.com/en/idylla-demo-request?utm_source=facebook&utm_medium=social&utm_campaign=1901_idylla-demo-request

16/01/2026

𝗡𝗲𝘅𝘁 𝘄𝗲𝗲𝗸, 𝘄𝗲 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗮𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝗕𝗮𝗺𝗯𝗲𝗿𝗴𝗲𝗿 𝗠𝗼𝗿𝗽𝗵𝗼𝗹𝗼𝗴𝗶𝗲𝘁𝗮𝗴𝗲!
📅 23-25 January | 🗺️ Bamberg, Germany

📣𝗗𝗼𝗻'𝘁 𝗺𝗶𝘀𝘀 𝗼𝘂𝘁 𝗼𝗻 𝗼𝘂𝗿 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗘𝗚𝗙𝗥 𝗰𝗼𝗺𝗽𝗮𝗰𝘁 𝗰𝗼𝘂𝗿𝘀𝗲! Join us 24 January at 09:30 in room K8 and learn how Idylla™ can deliver your EGFR results in only 3 hours!

👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗕𝗮𝗺𝗯𝗲𝗿𝗴 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://www.biocartis.com/en/news-events/events/bamberger-morphologietage-2025

14/01/2026

Molecular biomarker results in ONLY 3 HOURS!
💡 THINK IDYLLA™

Today, Biocartis offers tests supporting lung, skin, thyroid, colorectal, endometrial, blood, brain and breast cancer.

More information 👉 https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=1401_meet-idylla